Eisai Co., Ltd.

Profile narrative

Eisai Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, production, and sale of ethical pharmaceuticals. Its product portfolio includes treatments for neurological disorders such as Alzheimer's disease, oncology therapies, and medicines for gastrointestinal and cardiovascular conditions. The company markets its drugs in Japan and internationally through a network of subsidiaries and distributors. Eisai places a strong emphasis on creating medicines that address unmet medical needs, particularly in areas where treatment options are limited. Its operations span the full value chain from early discovery to post‑marketing surveillance.

Eisai maintains a global presence with offices, research centers, and manufacturing sites in more than thirty countries across Asia, the Americas, and Europe. The company employs thousands of staff who work in functions ranging from basic science to clinical development and commercial operations. Eisai’s revenue is generated primarily from sales of its prescription medicines, with a significant portion coming from markets outside Japan, especially the United States and Europe. The firm also collaborates with academic institutions, biotechnology partners, and other pharmaceutical companies to expand its pipeline. These collaborations help Eisai access novel technologies and share risks in drug development.

Eisai is recognized for its specialization in neurology and oncology, having brought to market notable products such as donepezil (Aricept) for Alzheimer’s disease and lenvatinib (Lenvima) for various cancers. The company invests heavily in research and development, allocating a substantial share of its budget to early‑stage discovery and clinical trials. Eisai’s commitment to innovation is reflected in its numerous patents and its participation in regulatory dialogues with agencies such as the FDA and EMA. Structurally, Eisai Co., Ltd. is an independent, publicly traded corporation listed on the Tokyo Stock Exchange, with wholly owned subsidiaries including Eisai Inc. in the United States and Eisai Europe Ltd. in the United Kingdom. This organizational structure supports its global strategy while maintaining centralized oversight from its headquarters in Tokyo, Japan.

Incidents

1 incident linked to this organisation.